NCT01171235

Brief Summary

The aim of the study is to find for one or more serum or tissue markers of molecular biology in head and neck cancer patients used for early diagnosis, predicting prognosis and being sensitive to chemotherapy and radiotherapy

Trial Health

35
At Risk

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Trial has exceeded expected completion date
Enrollment
200

participants targeted

Target at P75+ for all trials

Timeline
Completed

Started Jul 2010

Typical duration for all trials

Status
unknown

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

July 1, 2010

Completed
26 days until next milestone

First Submitted

Initial submission to the registry

July 27, 2010

Completed
1 day until next milestone

First Posted

Study publicly available on registry

July 28, 2010

Completed
1.3 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

December 1, 2011

Completed
1 year until next milestone

Study Completion

Last participant's last visit for all outcomes

December 1, 2012

Completed
Last Updated

July 28, 2010

Status Verified

March 1, 2009

Enrollment Period

1.4 years

First QC Date

July 27, 2010

Last Update Submit

July 27, 2010

Conditions

Keywords

Laryngeal NeoplasmsPharyngeal Neoplasms

Eligibility Criteria

Age15 Years - 75 Years
Sexall
Healthy VolunteersNo
Age GroupsChild (0-17), Adult (18-64), Older Adult (65+)
Sampling MethodNon-Probability Sample
Study Population

all of nasopharyngeal carcinoma, hypopharyngeal carcinoma or laryngeal carcinoma visited at ENT department of NanFang hospital

You may qualify if:

  • all of nasopharyngeal carcinoma
  • hypopharyngeal carcinoma or laryngeal carcinoma visited at ENT department of NanFang hospital

You may not qualify if:

  • all of above patients whose anticipated survival duration were less than 6 months

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Related Publications (1)

  • Yu BL, Peng XH, Zhao FP, Liu X, Lu J, Wang L, Li G, Chen HH, Li XP. MicroRNA-378 functions as an onco-miR in nasopharyngeal carcinoma by repressing TOB2 expression. Int J Oncol. 2014 Apr;44(4):1215-22. doi: 10.3892/ijo.2014.2283. Epub 2014 Jan 28.

Biospecimen

Retention: SAMPLES WITH DNA

blood and tissue samples

MeSH Terms

Conditions

Laryngeal NeoplasmsPharyngeal Neoplasms

Condition Hierarchy (Ancestors)

Otorhinolaryngologic NeoplasmsHead and Neck NeoplasmsNeoplasms by SiteNeoplasmsLaryngeal DiseasesRespiratory Tract DiseasesRespiratory Tract NeoplasmsOtorhinolaryngologic DiseasesPharyngeal DiseasesStomatognathic Diseases

Study Officials

  • Ping Xiang Li, doctor

    E.N.T department of NanFang hospital

    STUDY DIRECTOR

Study Design

Study Type
observational
Observational Model
COHORT
Time Perspective
PROSPECTIVE
Sponsor Type
OTHER

Study Record Dates

First Submitted

July 27, 2010

First Posted

July 28, 2010

Study Start

July 1, 2010

Primary Completion

December 1, 2011

Study Completion

December 1, 2012

Last Updated

July 28, 2010

Record last verified: 2009-03